Melanoma

In an analysis of a French melanoma database, 43% of patients treated with anti–PD-1 therapy experienced a late-onset immune-related adverse event, defined as an event occurring after ≥2 years of treatment. Read More ›

Nivolumab continues to be an effective adjuvant treatment for patients with resected high-risk melanoma at 4 years, with sustained recurrence-free and distant metastasis-free survival benefit compared with ipilimumab. Read More ›

Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V⁶⁰⁰-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read More ›

The latest analysis of the phase 3 EORTC 1325/KEYNOTE-054 clinical trial showed pembrolizumab to be superior to placebo after more than 3.5 years of follow-up on the end points of distant metastasis-free survival and relapse-free survival in patients with resected stage III melanoma. Read More ›

Melanoma is the most dangerous form of skin cancer.¹ The 5-year relative survival rate for Americans with distant melanoma is only 23%. The National Cancer Institute estimated that there were 91,270 new cases of skin melanoma and more than 9300 deaths from this disease in 2018. This deadly disease is also costly; in the United States, expenditures for the treatment of melanoma exceeded $3 billion in 2018. Read More ›

This clinical trial is the first study to show that this immunotherapy combination is as beneficial in controlling brain metastases as it is in treating extracranial metastases. Read More ›